Skip to content


The urgent need for alternatives to antibiotics in addressing Antimicrobial Resistance (AMR) arises from the growing crisis of multi-drug resistant (MDR) pathogens. Antibiotics have been a cornerstone of modern medicine, but their overuse and misuse have led to the emergence of bacteria and other microbes that are resistant to these drugs. This phenomenon threatens our ability to treat common infections, perform surgeries, and manage chronic conditions effectively. As antibiotic development lags behind the rapid evolution of resistance mechanisms in microbes, non-antibiotic alternatives offer a critical solution. Developing and adopting alternatives is essential to safeguard public health and ensure that we have effective tools to combat infections in the future.

Peptomer Therapeutics has created groundbreaking platform technologies capable of generating a diverse array of novel antimicrobial oligomers and peptidomimetics with efficacy against a wide spectrum of microorganisms.

Repurposing novel antimicrobial compounds: The conventional approach to antibiotic development faces constraints due to the myriad of resistance mechanisms employed by bacteria. Conversely, non-antibiotic alternatives offer promise in combating multidrug-resistant (MDR) pathogens. We’ve made a groundbreaking discovery by identifying antimicrobial polymers that have been in use for over three decades for non-therapeutic purposes and have a well-established safety profile. Despite their potent activity against numerous MDR bacterial strains, their systemic use has been limited due to the presence of unwanted impurities. To tackle the challenge of antimicrobial resistance (AMR), we’ve pioneered innovative methods to produce these molecules in a pure and potent form, allowing us to repurpose them as effective antimicrobials.

Novel antimicrobial peptidomimetics: Our innovation introduces novel monomers that enable the synthesis of a distinct class of antimicrobial peptides. Our unique platform empowers the creation and synthesis of a range of innovative antimicrobial peptidomimetics capable of targeting both bacteria and fungi within the same molecule.

Antimicrobial oligomers: Our innovation offers new monomers to facilitate the synthesis of a novel class of antimicrobial peptides. Through our unique platform, we can design and synthesize a series of cutting-edge antimicrobial peptidomimetics capable of targeting both bacteria and fungi within a single molecule.